High blood pressure medicine Rasilez gets approval in Japan

view article

Published at: www.pharmabiz.com

Novartis Targets Global Renin Angiotensin System Inhibition

July 12, 2009

Analysis by: GLG Expert Contributor

It has taken a long, long time form oral renin inhibition to come along, and Novartis is seeking to target glomeruli on 5 continents. The South East Asian market is potentially huge for the treatment of hypertension and Japan has a long tradition of willingness to participate in the battle to lower blood pressure by all means pharmacological. Whilst there are still few data to demonstrate superiority of Direct Renin inhibition over ACE inhibition in long term outcomes, the field of hypertension treatment is still expanding, no doubt in part, driven by consumer demand for the newest agent, and the side-effects, real, important or otherwise of current agents often reported more in anecdote than evidence based format. Novartis has an important role in the area of Renin-Angiotensin System inhibition, and this new approval will do no harm to that reputation and market share.